ArticleCNS drugs2026

From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer's Disease.

Robert Perneczky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.